Abstract
Simvastatin, an HMG-CoA reductase inhibitor, was administered to nine patients with hypercholesterolemia, and changes in the serum lipid levels as well as erythrocyte ghost lipid peroxide levels were examined at 0, 16, 32, and 48 weeks. The serum TC, apo-B, LDL-C, and EG-LPO levels were reduced significantly at 16 and 48 weeks, whereas no remarkable changes were observed in the serum TG, HDL-C, Lp(a), apo-A1, A2, C2, C3, E, or serum lipid peroxide levels. These findings suggest that simvastatin not only improves serum lipid levels but also inhibits lipid peroxidation of the erythrocyte membranes, and might be useful for preventing the progression of atherosclerotic vascular lesions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
